Login to Your Account



Gamida Cell's StemEx Improves Overall Survival in Phase II/III

By Marie Powers
Staff Writer

Tuesday, February 5, 2013
Israeli biotech Gamida Cell Ltd. moved lead product StemEx one step closer to becoming potentially the first allogeneic biologic cell product to achieve marketing approval in the U.S. and Europe.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription